{"id":361,"date":"2021-02-18T12:36:22","date_gmt":"2021-02-18T20:36:22","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=361"},"modified":"2021-03-04T14:35:40","modified_gmt":"2021-03-04T22:35:40","slug":"cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-004","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh_hk\/cloudbreak-receives-u-s-food-and-drug-administration-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-cbt-004\/","title":{"rendered":"Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-004"},"content":{"rendered":"<p><strong>Irvine, CA \u2013 February 18, 2021<\/strong> \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-004 to treat vascularized pinguecula.<\/p>\n<p>The Phase 2 clinical trial is a U.S.-based, randomized, double-masked, vehicle-controlled, multi-center trial evaluating the safety, tolerability and efficacy of CBT-004 ophthalmic emulsion when instilled twice daily (BID) for 28 days at the proposed doses of 0.01% and 0.024% in patients with vascularized pinguecula.<\/p>","protected":false},"excerpt":{"rendered":"<p>Irvine, CA \u2013 February 18, 2021 \u2013 Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-004 to treat vascularized pinguecula. The Phase 2 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":363,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts\/361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/comments?post=361"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts\/361\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/media\/363"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/media?parent=361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/categories?post=361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/tags?post=361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}